Trivalent MDCK cell culture-derived influenza vaccine Optaflu^® (Novartis Vaccines)

Abstract

Annual influenza epidemics continue to have a considerable impact in both developed and developing countries. Vaccination remains the principal measure to prevent seasonal influenza and reduce associated morbidity and mortality. The WHO recommends using established mammalian cell culture lines as an alternative to egg-based substrates in the manufacture of influenza vaccine. In June 2007, the EMEA approved Optaflu^®, a Madin Darby canine kidney cell culture-derived influenza vaccine manufactured by Novartis Vaccines. This review examines the advantages and disadvantages of cell culture-based technology for influenza vaccine production, compares immunogenicity and safety data for Optaflu with that of currently marketed conventional egg-based influenza vaccines, and considers the prospects for wider use of cell culture-based influenza vaccines.

Keywords::

• influenza pandemic
• influenza vaccine
• MDCK cell culture

Acknowledgements

The authors wish to acknowledge the editorial assistance provided by Ying Watt of the Canadian Center for Vaccinology.

Financial & competing interests disclosure

Scott Halperin has undertaken research studies with Novartis Vaccines on other vaccine products. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.